ORYZON announces First Patient In in ORY-2001 MS Phase IIA trial SATEEN and presents new data on ORY-2001 at the third annual ACTRIMS Forum 2018 in San Diego

MADRID, SPAIN and CAMBRIDGE MA.

• Posters to highlight the latest preclinical findings in MS and the outline of the recently initiated Phase IIA clinical trial

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the inclusion of the First Patient in the SAfety, Tolerability and Efficacy in an EPIGENETIC approach to treat Multiple Sclerosis, SATEEN, Phase IIA clinical trial with ORY-2001 in Multiple Sclerosis. The company further announced that it will present new data on ORY-2001 at the third annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018, which will take place February 1-3 at the Hilton San Diego Bayfront in San Diego, California.

Click here to see the full Press Release